{"id":"racemic-salbutamol","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nervousness/anxiety"},{"rate":"1-5","effect":"Palpitations"},{"rate":"1-5","effect":"Muscle cramps"},{"rate":"1-5","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL714","moleculeType":"Small molecule","molecularWeight":"239.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Salbutamol binds to beta-2 adrenergic receptors on bronchial smooth muscle, activating adenylyl cyclase and increasing intracellular cAMP, which leads to smooth muscle relaxation and bronchodilation. The racemic mixture contains both R- and S-enantiomers, though the R-enantiomer is the pharmacologically active form. It is used as a rapid-acting bronchodilator for acute relief of airway obstruction.","oneSentence":"Racemic salbutamol is a non-selective beta-2 adrenergic receptor agonist that relaxes airway smooth muscle and increases bronchial airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:37.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bronchospasm and reversible airway obstruction in asthma"},{"name":"Chronic obstructive pulmonary disease (COPD) exacerbations"},{"name":"Exercise-induced bronchoconstriction"}]},"trialDetails":[{"nctId":"NCT00585039","phase":"PHASE4","title":"Albuterol Versus Xopenex in Treatment of Acute Asthma in the Emergency Department (ED)","status":"COMPLETED","sponsor":"Phoenix Children's Hospital","startDate":"2005-09","conditions":"Asthma","enrollment":101},{"nctId":"NCT01229384","phase":"NA","title":"Randomized Controlled Trial Comparing Standard Versus Positive Pressure Nebulization in Infants With Bronchiolitis to Reduce Hospital Admissions","status":"WITHDRAWN","sponsor":"Phoenix Children's Hospital","startDate":"2011-10","conditions":"Bronchiolitis","enrollment":""},{"nctId":"NCT00665600","phase":"PHASE3","title":"Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":257},{"nctId":"NCT05173584","phase":"PHASE4","title":"Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects.","status":"UNKNOWN","sponsor":"University of Aleppo","startDate":"2021-11-04","conditions":"Hyperkalemia","enrollment":30},{"nctId":"NCT00831376","phase":"PHASE4","title":"Trough Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2009-01","conditions":"Asthma","enrollment":30},{"nctId":"NCT00124176","phase":"PHASE4","title":"Continuous Levalbuterol for Treatment of Status Asthmaticus in Children","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2004-04","conditions":"Asthma","enrollment":81},{"nctId":"NCT01656811","phase":"PHASE2","title":"A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2001-10","conditions":"Asthma","enrollment":146},{"nctId":"NCT00830882","phase":"PHASE4","title":"Peak Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol","status":"WITHDRAWN","sponsor":"University of Dundee","startDate":"2009-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT00073814","phase":"PHASE3","title":"Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-12","conditions":"Asthma","enrollment":80},{"nctId":"NCT00667407","phase":"PHASE3","title":"Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2000-11","conditions":"Asthma","enrollment":627},{"nctId":"NCT00685347","phase":"PHASE2","title":"Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-01","conditions":"Asthma, Bronchoconstriction","enrollment":33},{"nctId":"NCT00684866","phase":"PHASE2","title":"Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-01","conditions":"Asthma","enrollment":31},{"nctId":"NCT00685022","phase":"PHASE2","title":"Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-06","conditions":"Asthma","enrollment":49},{"nctId":"NCT00667797","phase":"PHASE4","title":"Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-03","conditions":"Asthma, COPD","enrollment":486},{"nctId":"NCT00684827","phase":"PHASE2","title":"A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-10","conditions":"Asthma","enrollment":32},{"nctId":"NCT00064389","phase":"PHASE3","title":"Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-01","conditions":"Asthma","enrollment":746},{"nctId":"NCT00685126","phase":"PHASE3","title":"Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2001-02","conditions":"Reactive Airways Disease (RAD)","enrollment":117},{"nctId":"NCT00073840","phase":"PHASE3","title":"Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-12","conditions":"Asthma","enrollment":386},{"nctId":"NCT00073827","phase":"PHASE3","title":"Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-05","conditions":"Asthma","enrollment":445},{"nctId":"NCT00064415","phase":"PHASE3","title":"To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-06","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema","enrollment":799},{"nctId":"NCT00685425","phase":"PHASE3","title":"Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-10","conditions":"Asthma, Bronchoconstriction","enrollment":62},{"nctId":"NCT00325767","phase":"PHASE4","title":"Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2004-05","conditions":"Mucociliary Clearance","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ventolin","ventolin"],"phase":"marketed","status":"active","brandName":"racemic salbutamol","genericName":"racemic salbutamol","companyName":"University of Dundee","companyId":"university-of-dundee","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Racemic salbutamol is a non-selective beta-2 adrenergic receptor agonist that relaxes airway smooth muscle and increases bronchial airflow. Used for Acute bronchospasm and reversible airway obstruction in asthma, Chronic obstructive pulmonary disease (COPD) exacerbations, Exercise-induced bronchoconstriction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}